A review of a major driver rehabilitation centre: a ten-year client profile.

Driver Rehabilitation Services at Bloorview MacMillan Centre in Toronto provide important assessment and rehabilitation services for persons with various physical, neurological, and medical disabilities. Each year, the programme sees approximately 700 to 800 clients. Since 1985, the earliest year for which records are currently available, the program has seen approximately 7300 clients. The client information filing system consists predominantly of paper reports filed alphabetically by hand. A comprehensive computer database program was implemented in 1996 to organize and analyze client-driver records more efficiently. A systematic random sample consisting of 364 records (5% of the total population) was examined to describe the characteristics of the population within five major study categories: demographics, administration, medical information, visual and perceptual abilities and driving record.

Driving skills in elderly persons with stroke: comparison of two new assessment options.

OBJECTIVE: To compare the effectiveness of two methods of assessing off-road driving skills that claim to predict on-road driving fitness of persons with stroke. METHOD: Fifty-six persons with stroke (age 44 to 82 yrs; mean, 60.2 yrs) completed the 2 off-road driving assessments along with standard clinical and on-road driving tests. MAIN OUTCOME MEASURES: Linear stepwise regression on 4 variables of the Dynavision Performance Assessment Battery (DPAB), the Cognitive Behavioral Driver's Inventory (CBDI) variable (composite score), and the variables of age, gender, and lesion side. RESULTS: A 4-minute endurance subtest from the DPAB was superior to the CBDI in predicting success/failure in the on-road driving test (75%). However, success on both the 4-minute endurance subtest from the DPAB and the CBDI tests significantly improved the prediction of on-road success. If participants passed the CBDI and the endurance test from the DPAB, they also passed the on-road assessment. CONCLUSION: Driving fitness of elderly persons with stroke can be assessed with reasonable accuracy using off-road tests, minimizing the expense and risk associated with on-road assessments in this population.

Prospective studies of outcome. Understanding mechanisms of change in patients with borderline personality disorder.

The authors propose a conceptual model of recovery from BPD that takes into account empiric findings regarding the dynamic relationships between severity of BPD symptoms, age, impulsivity, and duration of a healing relationship. The model assumes that each factor related to the course of BPD essentially lies on a continuum and interacts with the remaining important factors. The model also preserves the relative relationships, with age and impulsivity being primarily important and the duration of a healing relationship being independent but overall of less importance in modifying the course of illness. (Having said this, however, modifying the presence of a healing relationship may be more accessible for therapists.) By 7 to 10 years' follow-up, half of patients with BPD will be characterized as remitted. Efforts to keep these patients alive through the early course of the disorder will see many patients through to the resolution of the disorder. Impulsivity is a primary element of the disorder that predicts the course of BPD, with impulsivity becoming less as patients age. Efforts to modify the levels of impulsivity, such as rehabilitation for substance-abuse disorder, pharmacologic interventions, and cognitive-behavioral therapies to reduce impulsivity, may affect the course of the disorder. Exposure to an intimate relationship, such as a successful marriage, also may impact the course by allowing the person to be involved in a healing relationship. Additional studies are needed on the role of couple and marital interventions with BPD patients because the development of successful relationships may modify the course of the disorder. This model of change in BPD is conceptually heuristic and accounts for the complex interplay of factors that modify the course of BPD but accounts for the empiric findings to date. This model is also presented to assist clinicians in understanding and conceptualizing the primary features affecting recovery for these patients. As new findings become available, this model should be modified to reflect the nature of those findings and extend the understanding of the course of BPD and the factors that modify that course of illness.

The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia.

The purpose of the present study was to examine the relationship between neurocognitive deficits and self-reported quality of life in order to examine whether neurocognitive impairment interferes with any aspects of quality of life for patients with schizophrenia. Forty-two outpatients with stable chronic schizophrenia were assessed for neurocognitive deficits using a computerized test battery, and all patients completed a version of the Sickness Impact Profile (SIP) to assess their quality of life across a variety of domains. The neurocognitive assessment tests revealed significant deficits compared with normal control subjects, particularly with respect to impaired iconic memory and frontal functioning. Patients reported that their quality of life was compromised. Despite the substantiation of marked neurocognitive deficits and reduced quality of life, correlations between neurocognitive deficits and quality of life were largely nonsignificant or very weak. Symptom expression, however, particularly with regard to general psychopathology on the Positive and Negative Syndrome Scale (PANSS), was significantly associated with quality of life. These results suggest that neurocognitive deficits in schizophrenia, while often profound, appear to have little direct impact on the patient's perceived quality of life.

Quality of life measurement during antipsychotic drug therapy of schizophrenia.

The strategy for measuring quality of life and the choice of a rating scale should follow a rational scheme aimed at capturing the key components of quality of life of a specified clinical population. This is achieved through defining the purpose of the study, identifying the clinical population and its needs, developing a situation-specific quality of life model, and choosing a battery of psychometrically sound and user-friendly rating scales based on the model. Patients' self-reports and subjective feelings should be central to quality of life measurement, which should also monitor symptom severity, drug side effects, and psychosocial adjustment. This article describes the application of these principles in the context of antipsychotic drug therapy of schizophrenia and identifies potential problems that may arise from the conceptual, psychometric, clinical, and other feasibility issues. The highly subjective nature of the disorder, together with the poor insight, lack of motivation, and neurocognitive deficits of those who are afflicted, poses special difficulties for obtaining and interpreting patients' quality of life appraisals in schizophrenia.

Neurocognitive deficits and neurological signs in schizophrenia.

OBJECTIVE: This is a comprehensive study designed to examine the association between specific clusters of neurological abnormalities and several clinically relevant aspects of schizophrenia such as positive and negative symptoms, neurocognitive deficits and psychosocial performance. METHODS: Thirty-seven clinically stable schizophrenic (DSM-III-R) patients maintained on antipsychotic medication were comprehensively examined and Convit's Quantified Neurologic Scale (QNS) was completed. In addition, patients' psychopathology was rated on the Positive and Negative Syndromes Scale (PANSS); psychosocial performance was rated on the Global Scale of Adaptive Functioning (GAF) and the Social Performance Schedule (SPS); and neurocognitive deficits were measured with a computer-assisted neurocognitive test battery, COGLAB. The association between these factors was determined using Pearson's correlation coefficients. RESULTS: Frontal and soft neurological scores on the QNS correlated significantly with negative syndrome scores (r = 0.45-0.51, p < 0.05) and general psychopathology scores (r = 0.46-0.49, p < 0.02) on PANSS; poor psychosocial performance on GAF (r = 0.43-0.56, p < 0.02) and SPS (r = 0.37-0.54, p < 0.007); and performance on the span of apprehension (r = 0.48-0.67, p < 0.0001), backward masking (r = 0.34-0.54, p < 0.01) and Wisconsin card sorting (r = 0.48-0.67, p < 0.001) tasks. CONCLUSION: Frontal and soft neurological signs in schizophrenic patients are associated with prominent negative symptoms, relatively poor psychosocial performance and significantly more cognitive impairment. Past research has associated soft neurological signs, cognitive impairment and structural brain abnormalities with poor outcome and prognosis in patients with schizophrenia.

A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation.

The utility of quality of life (QOL) as an evaluative tool in clinical psychiatric research and drug trials could be enhanced by developing appropriate conceptual models of QOL, specific for psychiatric disorders. In our proposed model, QOL of individuals maintained on antipsychotic drug therapy for schizophrenia, is viewed as the subject's perception of the outcome of an interaction between severity of psychotic symptoms, side-effects including subjective responses to antipsychotic drugs, and the level of psychosocial performance. In order to test the validity of the model in clinical setting, we selected a sample of 62 schizophrenic patients clinically stabilized on antipsychotic drug therapy, and measured their subjective QOL and other potentially relevant clinical and psychosocial factors. Standardized scales including the positive and negative syndromes scale (PANSS), abnormal involuntary movements scale (AIMS), Hillside Akathisia scale (HAI), and the social performance schedule (SPS) were used for this purpose. Results of a multiple regression analysis using subjective quality of life as the outcome variable, indicated that severity of schizophrenic symptoms (partial R2 = 0.32, p < 0.0001) and subjective distress caused by akathisia (partial R2 = 0.11, p < 0.01) and neuroleptic dysphoria (partial R2 = 0.06, p < 0.05), accounted for nearly half of the variance, while the contribution from the psychosocial indicators was negligible. These results broadly endorse key aspects of the proposed model, and suggest further studies in this direction. These results experiences during antipsychotic therapy can enhance patients' QOL. This conceptual model has been developed with particular focus on the impact of antipsychotic medications on the QOL of persons with schizophrenia. As such, it is more applicable to clinical trials of new antipsychotic medications but may not be broad enough to be applicable for other social or vocational interventions.

Neurocognitive correlates of positive and negative syndromes in schizophrenia.

OBJECTIVE: To identify the neurocognitive correlates of positive and negative schizophrenic syndromes using a battery of information-processing measures as the principal method of evaluation. METHOD: Fifty-two treated, symptomatically stable, schizophrenic (DSM-III-R) patients and 24 age-matched, healthy volunteers were administered a computerized cognitive test battery (COGLAB). The battery included measures of preattentional, attentional, conceptual, and psychomotor performance. The patients' psychopathology was rated with the positive and negative syndromes scale (PANSS), which derived scores for positive symptoms, negative symptoms, general psychopathology, and insight. RESULTS: Compared with controls, schizophrenic patients, as a group, showed significant deficits on all of the neurocognitive tasks. Impaired performance on the backward masking, span of apprehension, and Wisconsin card sorting tasks correlated significantly with negative symptoms (r = 0.27-0.40), general psychopathology (r = 0.29-0.42) and impaired insight (r = 0.34-0.52), but no clear association was found between positive symptom scores and neurocognitive deficits. CONCLUSIONS: Schizophrenic patients with predominantly negative symptoms and impaired insight seem to exhibit more severe neurocognitive deficits, which lends support to the evolving concept of schizophrenia subtypes and their distinctive neurobiological mechanisms.

Measuring quality of life in patients with schizophrenia.

Schizophrenia is a chronic disabling illness that affects about 1% of the population. It is a heterogenous disorder with variable aetiological, prognostic and treatment response patterns. Its course is generally long term, with acute psychotic exacerbations that may require hospitalisation. The cornerstone of clinical management is the use of antipsychotic (neuroleptic) medications. Although these are effective, they can cause adverse effects that may impact negatively on the functional status of the individual. Early studies of quality of life in schizophrenia were mainly concerned with the development of techniques to identify patients' needs in the community. Difficulties encountered in these studies included: lack of agreement on definition of quality of life; lack of appropriate integrative conceptual models; concerns about reliability of patients' self-reports about their quality of life; and the lack of standardised quality-of-life measures appropriate for schizophrenia. A number of disease-specific or generic scales have subsequently been used for measurement of quality of life in schizophrenia. The list of disease-specific scales is extensive; unfortunately, many of them were used only in a single study or their psychometric properties were not specified. Generic scales can be applied across various types and severity of illness, as well as in different health interventions across demographic and cultural groups. Medication costs in schizophrenia represent only a small fraction of the total cost of the illness. However, pharmacoeconomic studies have attracted much interest as a result of the high cost of newly introduced medications and of concern about the limitations of antipsychotic medications, particularly their adverse effects, as exemplified by the reintroduction of clozapine for the treatment of refractory schizophrenia. Few studies have combined quality-of-life measures with cost analysis in schizophrenia; a number of these have methodological shortcomings. Many studies are retrospective in nature, and in most the number and length of hospitalisations has been used as the parameter for cost analysis, which can introduce bias depending on the varying approaches to hospitalisation. We conclude that the following factors are important in choosing or developing a quality-of-life measure for schizophrenia: quality of life is a multidimensional concept that has to be reflected in its measurement; the scale has to be appropriate for the purpose as well as the population studied; measurement has to include patients' self-reports about their quality of life; measures should include only items that are relevant and expected to change; single-item global measures are useful only when combined with multidimensional measures; in developing new scales, psychometric properties have to be established as well as being field-tested.

Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.

The concept of subjective response to neuroleptics in schizophrenia was reviewed with particular focus on scales for its measurement. The significance of recognizing such a phenomenon early on in the course of treatment has been illustrated by research data linking it to compliance, clinical improvement, quality of life, suicidal behaviour and comorbid drug abuse. Negative subjective response to neuroleptics has been identified as a strong predictor of compliance and outcome. Awareness of this subjective response in the management of the acute phase of the illness would require the physician to develop specific or additional approaches to the management of such dysphoric patients on neuroleptics at the time of discharge.

The effects of bright light treatment on the symptoms of fibromyalgia.

OBJECTIVE: To investigate the effects of bright light treatment on the symptoms of pain, mood, and sleep in patients with fibromyalgia (FM) reporting seasonality of symptoms on the Seasonal Pattern Assessment Questionnaire (SPAQ). METHODS: A randomized 10 week crossover study compared the effects of 4 weeks of "visible electromagnetic fields" (EMF) (light condition; mean 4750 lux, SD 2337 lux) to 4 weeks of "nonvisible EMF" (no light condition) in 14 patients with FM having a minimum SPAQ score of 11. The light visor system (Bio-Brite) was fitted with an opaque filter for the "nonvisible EMF" control condition. RESULTS: No significant differences were found between treatment conditions on tenderness measured with dolorimetry, self-ratings of sleep, pain, mood, and global measures. Mood was not related to pain or sleep. There was significant reduction in depression scores and subjective pain, but increased tenderness and nocturnal awakenings related to time. CONCLUSION: The were no significant differences between the light and no light conditions on pain, mood, or sleep in patients with FM reporting seasonality of symptoms. No relationship was found between mood and the symptoms of FM (i.e., pain, sleep, and fatigue).

Borderline psychopathology and recurrences of clinical disorders.

This prospective cohort study of patients with borderline psychopathology reports on the clinical disorders occurring during the course and at 7-year follow-up. Subjects with persistent versus remitted borderline personality disorder (BPD) are compared. The relationship between the initial levels of borderline psychopathology and the occurrence of clinical disorders on follow-up is examined. Consecutive admissions to inpatient units were screened for borderline characteristics. This resulted in a sample of 130 subjects, 88 of whom were positive for BPD based on the Diagnostic Interview for Borderlines. At 7-year follow-up, 81 (62.3%) subjects were reinterviewed in person, 6 (4.6%) suicided, 2 (1.6%) were decreased, 36 (27.7%) refused to participate, and 5 (3.8%) could not be located. Twenty-seven of 57 (47.4%) who initially were positive for BPD were rediagnosed at 7-year follow-up (the persistent group) and 30 (52.6%) were no longer diagnosed as BPD (the remitted group). The persistent individuals were significantly more likely to be diagnosed as having major depression, dysthymia, and other psychiatric disorders than the remitted group. The persistent group had significantly more episodes of substance abuse over the follow-up period compared with the remitted group. Individuals with persistent BPD suffered more episodes of clinical disorders over the follow-up period and the initial level of borderline psychopathology predicted the recurrence of major depression.

Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life.

The phenomenon of subjective response to antipsychotic medications in schizophrenia was reviewed, focusing on validity, measurement, implications for clinical outcome and quality of life. Recommendations were made on improvements in research approaches to important factors that may contribute to the genesis of this phenomenon. Clinicians should pay attention to the subjective complaints of their patients about medications and not ignore them as unreliable. Researchers should not dismiss research into subjective experiences as non-scientific, because it provides valuable information on recognizing psychopathology and for improving the management of patients.

The effects of Dynavision rehabilitation on behind-the-wheel driving ability and selected psychomotor abilities of persons after stroke.

OBJECTIVE: Many conventional rehabilitation exercises, such as pencil-and-paper and computer tasks, may not train perceptual and motor skills as applied to a complex, multiskill activity such as driving. The present study examined the usefulness of the Dynavision apparatus for driving-related rehabilitation. The Dynavision was designed to train visual scanning, peripheral visual awareness, visual attention, and visual-motor reaction time across a broad, active visual field. METHOD: Ten persons with a cerebrovascular accident participated in the study. All had failed behind-the-wheel driving assessments. Subjects participated in a 6-week Dynavision training program using exercises designed to impose various motor, perceptual, and cognitive demands. RESULTS: Dynavision training resulted in significantly improved behind-the-wheel driving assessments as compared to expected outcomes. Comparisons between pretests, posttests, and follow-up tests on a number of Dynavision, response, and reaction time variables showed significant improvements and maintenance effects. Dynavision performance, and, to a lesser extent, choice visual reaction and response times, were found to differentiate between persons assessed as safe and unsafe to drive, and between older and younger drivers. Subject self-reports suggested that a variety of training-related improvements had occurred in everyday functioning. CONCLUSION: Dynavision training shows some rehabilitative promise for improving driving and basic psychomotor skills. Future research on the benefits and limitations of this apparatus should use finer laboratory skill measures and more comprehensive tests of driving and daily functioning to assess more thoroughly skill improvements in persons after stroke.

Borderline personality disorder and substance abuse: consequences of comorbidity.

The objective of this paper was to examine the prognostic significance of borderline personality disorder (BPD) and substance abuse in a cohort of former inpatients screened for BPD and followed up prospectively seven years after the index admission. The impact of comorbidity on borderline psychopathology, impulsivity and psychosocial functioning was examined. The original cohort was assembled between April 1983 and December 1985. Admissions were screened for borderline characteristics which resulted in a sample of 130 subjects, 88 of whom were positive for BPD based on the Diagnostic Interview for Borderlines. At seven years follow-up, 81 out of 130 (62.3%) subjects were re-interviewed. Six (4.6%) had committed suicide, two (1.5%) were deceased and 41 (31.6%) were lost to follow-up. The subjects with BPD and substance abuse were significantly differentiated from subjects with BPD only, substance abuse only and neither disorder on the basis of demonstrating more borderline psychopathology and more self-destructive and suicidal thoughts and behaviours. Probands with initial diagnoses of BPD and substance abuse were twice as likely to be diagnosed BPD on follow-up as probands with initial diagnosis of BPD only (relative risk = 2.19, 95% CI, 1.21 to 3.97). These findings and other research suggest that patients with comorbid BPD and substance abuse should be encouraged to focus on their abuse problems as a priority.

Electrophysiological recording and analysis during protracted continuous work experiments.

A system is described that allows electrophysiological data to be collected and analysed from sleep loss studies involving continuous cognitive work. This system needed to satisfy two major requirements. First, the electrophysiological hardware had to be able to record extended periods of physiology (often lasting 80 h) from multiple electrode sites and yet be portable enough to allow subject mobility. Second, a comprehensive yet flexible procedure had to be developed to temporally map the physiology to critical experimental events (e.g., all the behavioural tasks, sleeping and napping periods). The resulting system uses the Oxford Medilog 9000 for data acquisition and playback as well as a custom software environment to digitize and analyse these data.

T-wave amplitude utility revisited: some physiological and psychophysiological considerations.

The last decade has seen some quite polemicized discussions concerning the utility of T-wave amplitude as a psychophysiological measure, but more recent reports indicate that we are now moving into a more empirically oriented and analytic examination of this topic. Such a report is one by Contrada et al. (1989), who manipulated sympathetic (beta-adrenergic) influences both pharmacologically and behaviorally, and whose main conclusion was that their results "support the hypothesis that T-wave is significantly affected by beta-sympathetic influence on the heart". However, we question their other conclusion that "a nonspecific effect of heart rate change on T-wave amplitude would also account for these results", and also suggest that their discussion of the "implications for the utility of T-wave amplitude in psychophysiological research" bears further consideration. In particular, for psychophysiologists, of fundamental importance is the distinction between T-wave amplitude's utility as a physiological index and its utility as a psychophysiological index. Concerning the former issue, we consider: (a) the alpha/beta adrenergic distinction, (b) inappropriate T-wave amplitude augmentation effects to sympathomimetic stimulation, (c) the nonspecific-response-to-tachycardia argument, and (d) the view of pulse transit time as a criterial standard, rather than as a candidate index. Regarding the issue of psychophysiological index utility, we consider: (a) dependent-variable sensitivity, drawing a further distinction between reactive and specific sensitivity, and (b) independent-variable-manipulation effectiveness.

Cardiac regulation in bulimia nervosa.

Heart rate and vagal tone were assessed during sleep and bed rest conditions in nine patients with bulimia nervosa (BN), six patients with concomitant anorexia nervosa and bulimia nervosa (AN + BN) and five control subjects. During bed rest conditions AN + BN patients had significantly lower heart rates than BN or control subjects. During sleep, the heart rate differed significantly for all three groups. The AN + BN group had a significantly lower heart rate than either the BN or control groups and the BN group had a significantly lower heart rate than controls. On the other hand, measures of vagal tone, based on respiratory sinus arrhythmia, were significantly elevated in both patient groups compared to controls. These findings suggest that the bradycardia during sleep in BN patients may be primarily due to hypervagal activity, but the greater bradycardia demonstrated in those patients with both AN and BN may result from hypervagal activity coupled with reduced sympathetic activity.